Scynexis’ Phase III Success Brings New Antifungal Class Closer To Approval
Biotech plans to file its first-in-class triterpenoid agent for approval in 2020 following a second Phase III study in acute vulvovaginal candidiasis. Beyond that, it hopes for a supplemental approval in recurrent VVC.
You may also be interested in...
Scynexis highlights enrollment exceeding expectations in Phase III VVC trials; Daré prepares to enter Phase III to treat BV.
Positive top-line results from the Phase IIb DOVE study of Scynexis's SCY-078, and progress with a new intravenous formulation, suggest the US biotech's new triterpenoid could be the first of a new class of antifungal agents for serious infections.
The increasing threat of treatment-resistant Candida auris fungal infections suggests the need for greater development incentives, CEOs of three antifungal drug developers told the recent BIO annual meeting.